KRAS and non-small cell lung carcinoma: This can be achieved by inducing immune checkpoints, secreting specific cytokines, or producing chemokines that recruit specific cell types.13 Recent studies have shown that KRAS‐mutant NSCLC expresses higher levels of PD‐L1 protein14, 15, 16 compared to corresponding wild‐type tumors.